Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.65 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081491 | 1.00 | GBA1 (0.65) | GBA1FUCA1ACHEMAPTS1PR1 | |
| SCHEMBL14759418 | 0.88 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL14759416 | 0.88 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL1190716 | 0.88 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL742926 | 0.88 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL12616527 | 0.85 | FUCA1 (0.50) | GBA1FUCA1ACHEMAPTS1PR1 | |
| SCHEMBL20463841 | 0.85 | FUCA1 (0.50) | GBA1FUCA1ACHEMAPTS1PR1 | |
| SCHEMBL14302242 | 0.85 | RORC (0.56) | GBA1FUCA1ACHEMAPTS1PR1 | |
| SCHEMBL12616175 | 0.85 | FUCA1 (0.50) | GBA1FUCA1ACHEMAPTS1PR1 | |
| SCHEMBL20901984 | 0.84 | FUCA1 (0.60) | GBA1FUCA1ACHEMAPTS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| CN-101175724-B | pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-07 | — | — | CN | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| CN-101175724-A | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | GBA1 2653/4885FUCA1 3845/4885ACHE 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.